1. Introduction
===============

Lung cancer is the leading cause of cancer-related death in China and second most common in women after breast cancer.^\[[@R1]\]^ According to histological type, 2 broad classes are distinguished: nonsmall cell lung carcinoma (NSCLC) and small cell lung carcinoma. Surgical resection is the best method of treatment for early-stage NSCLC. However, tumor recurrence is very common after surgery. Tumor, node, and metastasis (TNM) stage, histology, and mutation status are significant predictors of tumor recurrence and prognosis.^\[[@R2]\]^ Primary lung cancers most commonly metastasize to the brain, bones, liver, and adrenal glands.^\[[@R3]\]^

Tumor recurrence after treatment is becoming a vital point to prolong the overall survival nowadays. Chemotherapy used to be an effective and widely used treatment for patients with tumor recurrence. During the last decade, target therapy and immunotherapy have been approved for the treatment of lung cancer. With an increasing understanding of the pathogenesis, combined modality therapy has been increasingly identified by clinicians.

In this paper, we will give an introduction to a female patient who received a radical surgery and was pathology diagnosed as lung adenocarcinoma. However, 8 months after surgery, a tonsillar metastasis was detected as a mass arising from the right tonsil. Postoperative pathology confirmed tonsillar metastasis of lung cancer. Gene sequencing confirmed the G719S mutation in exon 18 of the epidermal growth factor receptor (*EGFR*) gene and the patient received target therapy with icotinib. Nevertheless, 14 months after surgery, this patient presented with multiple brain metastases. Radiotherapy and chemotherapy were given to this patient then. But they were not very responsive either. Finally, the patient died of respiratory failure 26 months after surgery.

2. Case presentation
====================

A 59-year-old woman was admitted to our hospital for finding a lung nodule in physical examination. In the laboratory tests and physical examination, no remarkable abnormality was detected and the patient\'s blood pressure, serum potassium, blood glucose level, and glucose tolerance were all in normal range. No remarkable medical, family, and psychosocial history was observed. The computer tomography (CT) scan identified a ground-glass nodule (2 × 1.5 × 1.5 cm) on the left inferior lobe (Fig. [1](#F1){ref-type="fig"}). No enlarged lymph nodes or distant metastasis were detected on contrast-enhanced CT. Brain magnetic resonance imaging (MRI) and bone scintigraphy did not detect any other metastases.

![Chest computed tomography scan of this patient detected a ground-glass nodule (2 × 1.5 × 1.5 cm) on the left inferior lobe.](medi-96-e9003-g001){#F1}

Being primary diagnosed with early-stage lung cancer, the patient received a wedge resection and the intraoperative rapid frozen section confirmed lymphoma, and then the tumor was completely resected through lobectomy and systematic mediastinal lymphadenectomy. Grossly, the 2 tumor foci measured 1.5 × 2 cm in size. Histologically, the tumor consisted of abnormal differentiated glandular structure with staining positive for mucin (Fig. [2](#F2){ref-type="fig"}). Immunohistochemically, CD7, TTF-1, NapsinA were positive and Ki-67 labeling index was 30%. On the basis of these features, the diagnosis of lung adenocarcinoma was made (T1N0M0).

![Histopathological examination of the surgical specimen revealed abnormal differentiated glandular structure with staining positive for mucin (hematoxylin and eosin staining, original magnification ×10).](medi-96-e9003-g002){#F2}

However, 8 months after surgery, this patient coughed up a bloody mass. She received laryngealendoscopy examination and it detected a mass arising from the right tonsil. An incisional biopsy of tonsillar lesion suggested metastasis of the carcinoma from the palatine tonsils to the cervical lymph. The patient underwent a tonsillectomy and the pathology confirmed the tonsillar metastasis of lung cancer. Gene sequencing confirmed the G719S mutation in exon 18 of the *EGFR* gene and the patient received target therapy with icotinib (Fig. [3](#F3){ref-type="fig"}). Whereas, multiple brain metastases were detected in brain MRI 14 months after surgery and then the patient received radiotherapy (DT 2000cGy) for 10 times. After that, chemotherapy (pemetrexed and platinum) for 4 cycles, bevacizumab and chemotherapy was also given to this patient successively. But they all did not work well. Finally, the patient died of respiratory failure 26 months after surgery.

![G719S mutation in exon 18 of the *EGFR* gene detected by direct Sanger sequencing of biopsied samples from the resected tonsil. It causes a flame shifting change with glycine (The codon change from GGC to AGC).](medi-96-e9003-g003){#F3}

3. Discussion
=============

Tumor recurrence after surgery of lung cancer is quite common. Therefore, clinicians have focused more recently on additional treatments after tumor recurrence. Treatments for advanced or recurrent NSCLC included cytotoxinic chemotherapy with platinum-based agents, EGFR-tyrosine kinase inhibitors (TKIs) for EGFR mutant patients, crizotinib for *ALK* gene rearrangement, and so on.^\[[@R4]\]^ Individual comprehensive therapy is becoming a mainstream in the treatment of advanced NSCLC nowadays.

In our case, pathological stage was just T~1~N~0~M~0~. Immunohistochemically, Ki-67 labeling index was only 30%. Generally, this patient should enjoy a good prognosis.^\[[@R2],[@R5]\]^ However, tonsillar metastasis occurred just 8 months after surgery, which is a very rare metastatic site of lung cancer. There are no systematic data about the prognosis of lung cancer patients with tonsillar metastasis. Thereafter, the patient received target therapy, radiotherapy, and chemotherapy successively. But the duration of therapy is unsatisfactory. The tumor recurred soon after surgery and progress very fast, what is beyond our expectation.

Except TNM staging and pathological type, we found that gene sequencing confirmed G719S mutation in this patient. G719S mutation located in exon 18 of EGFR and can cause a flame shifting change with glycine and it turns to be serine and it accounts for 2% of all EGFR mutations in lung cancer.^\[[@R6]\]^ In a preclinical study, it shows the oncogenic potential and EFGR-TKIs sensitivity.^\[[@R7]\]^

However, target therapy with EGFR-TKIs is not very effective in our case. Moreover, radiotherapy and chemotherapy did not work well either. We suppose that G719S mutant may be the cause of poor responsive to treatment. The overall progression-free survival (PFS) of patients with G719S mutant is just 4 months, which is lower than median PFS of EGFR-mutated patients.^\[[@R8],[@R9]\]^ One possible mechanism to explain this is the EGFR-TKIs binds looser to EGFR G719S mutation than to L858R mutation, the most mutation in NSCLC.^\[[@R6],[@R7]\]^ Some clinical studies also indicate that G719S mutation is somewhat more resistant to gefitinib.^\[[@R8]\]^

Although current study indicates G719S mutant may be a poor prognostic factor of lung adenocarcinoma, specific treatment for such patients is not taken seriously yet. Some literatures suggest that afatinib and neratinib may be more sensitive to EGFR G719S mutation.^\[[@R10],[@R11]\]^ But it warrants further validation.
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